Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
Public ClinicalTrials.gov record NCT01877668. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a 12-month study investigating the effectiveness and safety of tofactinib in treating the signs and symptoms of active psoriatic arthritis and improving physical function and preserving bone structure in patients with an inadequate response to a traditional, nonbiologic disease-modifying antirheumatic drug. Adalimumab is used as a comparator.
Study identification
- NCT ID
- NCT01877668
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 422 participants
Conditions and interventions
Conditions
Interventions
- Tofacitinib 5 mg BID Drug
- Tofacitinib 10 mg BID Drug
- Adalimumab Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 20, 2014 (Actual)
- Primary completion
- Dec 18, 2015 (Actual)
- Completion
- Dec 18, 2015 (Actual)
- Last update posted
- Jul 6, 2017
2014 – 2015
United States locations
- U.S. sites
- 24
- U.S. states
- 15
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rheumatology Associates, PC | Birmingham | Alabama | 35205 | — |
| Rheumatology Associates of North Alabama, PC | Huntsville | Alabama | 35801 | — |
| Arizona Arthritis & Rheumatology Associates, P.C. | Glendale | Arizona | 85306 | — |
| Medvin Clinical Research | Covina | California | 91723 | — |
| Desert Medical Advances | Palm Desert | California | 92260 | — |
| Advances In Medicine (X-Rays) | Rancho Mirage | California | 92270 | — |
| San Diego Arthritis Medical Clinic | San Diego | California | 92108 | — |
| Millennium Research | Ormond Beach | Florida | 32174 | — |
| Arthritis Center, Inc. | Palm Harbor | Florida | 34684 | — |
| Klein & Associates, M.D., P.A. | Hagerstown | Maryland | 21740 | — |
| Clinical Pharmacology Study Group | Worcester | Massachusetts | 01605 | — |
| St. Paul Rheumatology, PA | Eagan | Minnesota | 55121 | — |
| Physician Research Collaboration, LLC | Lincoln | Nebraska | 68516 | — |
| Dartmouth-Hitchcock Medical Center (DHMC) | Lebanon | New Hampshire | 03756 | — |
| Paramount Medical Research & Consulting, LLC | Middleburg Heights | Ohio | 44130 | — |
| Altoona Center for Clinical Research | Duncansville | Pennsylvania | 16635 | — |
| Low Country Rheumatology, PA | Charleston | South Carolina | 29406 | — |
| Pioneer Research Solutions, Inc. | Houston | Texas | 77008 | — |
| Drug Shipment/Storage: Huntsman Cancer Hospital at the University of Utah | Salt Lake City | Utah | 84112 | — |
| University of Utah Hospital & Clinics | Salt Lake City | Utah | 84132 | — |
| Dynacare Laboratories (Specimen processing for shipment) | Seattle | Washington | 98122 | — |
| Investigational Drug Service Pharmacy, Swedish Medical Center. | Seattle | Washington | 98122 | — |
| Seattle Rheumatology Associates | Seattle | Washington | 98122 | — |
| Swedish Medical Center | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 99 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01877668, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 6, 2017 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01877668 live on ClinicalTrials.gov.